+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro proliferative response of chronic lymphocytic leukemia



In vitro proliferative response of chronic lymphocytic leukemia



La Ricerca in Clinica E in Laboratorio 7(2): 124-135



The peripheral blood lymphocytes of 13 previously untreated chronic lymphocytic leukemia (CLL) patients showed a decreased and delayed response in vitro to plant mitogens (PHA and PWM) and specific antigens (PPD and MLC). In addition, the serum of these patients inhibited the mitotic reactivity of both autologous and homologous normal lymphocytes. Since incubation with CLL serum did not affect the SRBC-rosetting capacity of normal lymphocytes, we believe that CLL serum interferes with some metabolic stage in blastogenesis rather than at the level of mitogen membrane interaction. The in vitro transformation of lymph node, bone marrow and peripheral blood lymphocytes in some of these patients was also investigated. Stimulation of peripheral blood cells with plant mitogens resulted in a more serious impairment of the response than that found with bone marrow and lymph node cells. This could be explained by the fact that, although CLL is a widespread lymphoproliferative disorder, some preferential homing of normally reactive cells in the bone marrow and lymph nodes cannot be excluded. Finally, since no stimulation was observed in mixed leukocyte cultures (MLC), our experiments provide evidence that no antigenic differences are detectable in CLL lymphoid populations.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040392548

Download citation: RISBibTeXText

PMID: 144313


Related references

In vitro proliferative response of chronic lymphocytic leukemia behavior of bone marrow lymph node and peripheral blood lymphocytes and the effect of autologous serum on mitogen induced reactivity. Ricerca in Clinica e in Laboratorio 7(2): 124-135, 1977

Epstein barr virus ebv infected clone in the leukemia cell population of a chronic lymphocytic leukemia ll patient with proliferative advantage in vitro but not in vivo. Scandinavian Journal of Immunology 32(4): 402, 1990

The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. Leukemia Research 34(9): 1189-1194, 2010

Heterogenous proliferative response of b chronic lymphocytic leukemia b cll cells to different activation signals and il 2. Experimental Hematology 19(6): 542, 1991

Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23. Leukemia and Lymphoma 14(3-4): 311-318, 1994

The proliferative response to CpG ODN stimulation predicts disease progression in B-cell chronic lymphocytic leukemia.. 2007

Chronic lymphocytic leukemia in association with a 2nd lympho proliferative disorder response to chemo therapy in 2 cases. Medical and Pediatric Oncology: 111-116, 1979

Positive effects of interferon-alpha on B cell-type chronic lymphocytic leukemia proliferative response. Journal of Immunology 140(3): 774-778, 1988

Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Annals of Internal Medicine 110(3): 236-238, 1989

Lack of proliferative and differentiative response of chronic lymphocytic leukemia b lymphocytes to t dependent or t independent b cell mitogens evidence for intrinsic defect of leukemic cells. Proceedings of the American Association for Cancer Research and American Society of Clinical Oncology 21: 251, 1980

The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors. Blood 69(6): 1667-1673, 1987

Chronic lymphocytic leukemia cells activated in vitro reveal cellular changes that characterize b pro lymphocytic leukemia and immuno cytoma. Scandinavian Journal of Immunology 17(5): 397-402, 1983

The Src-AbI kinase inhibitor dasatinib (BMS-354825). shows anti-proliferative and anti-apoptotic effects in chronic lymphocytic leukemia (CLL) cells in vitro.. 2007